Aura Biosciences Q3 2026 Earnings Date & Estimates

Aura Biosciences (NASDAQ:AURA) is a clinical-stage biotechnology company focused on developing precision oncology therapies that selectively target and destroy cancer cells while preserving surrounding healthy tissue. The company’s technology platform uses tumor-targeting virus-like particles and light-activated compounds to deliver localized anticancer treatment.

Aura’s lead product candidate is belzupacap sarotalocan, also known as AU-011, an investigational therapy designed for the treatment of primary choroidal melanoma, a rare cancer of the eye. AU-011 is administered locally and activated with near-infrared light, with the goal of treating tumors while reducing damage to vision-preserving ocular structures. The company has also evaluated the platform’s potential applications in other solid tumors.

Aura Biosciences was founded in 2009 and is headquartered in Cambridge, Massachusetts. The company’s research and clinical development activities are focused on oncology, with clinical programs involving specialized medical centers and patients in multiple regions. Elisabet de los Pinos, Ph.D., the company’s founder, serves as chief executive officer.